Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement by Moher, David et al.
Moher et al. Systematic Reviews 2015, 4:1
http://www.systematicreviewsjournal.com/content/4/1/1RESEARCH Open AccessPreferred reporting items for systematic review
and meta-analysis protocols (PRISMA-P) 2015
statement
David Moher1*, Larissa Shamseer1, Mike Clarke2, Davina Ghersi3, Alessandro Liberatiˆ, Mark Petticrew4,
Paul Shekelle5, Lesley A Stewart6 and PRISMA-P GroupAbstract
Systematic reviews should build on a protocol that describes the rationale, hypothesis, and planned methods of the
review; few reviews report whether a protocol exists. Detailed, well-described protocols can facilitate the understanding
and appraisal of the review methods, as well as the detection of modifications to methods and selective reporting in
completed reviews. We describe the development of a reporting guideline, the Preferred Reporting Items for
Systematic reviews and Meta-Analyses for Protocols 2015 (PRISMA-P 2015). PRISMA-P consists of a 17-item checklist
intended to facilitate the preparation and reporting of a robust protocol for the systematic review. Funders and those
commissioning reviews might consider mandating the use of the checklist to facilitate the submission of relevant
protocol information in funding applications. Similarly, peer reviewers and editors can use the guidance to gauge the
completeness and transparency of a systematic review protocol submitted for publication in a journal or other
medium.Background
Systematic reviews are the reference standard for syn-
thesizing evidence in health care because of their meth-
odological rigor. They are used to support the
development of clinical practice guidelines and inform
clinical decision-making. They are becoming increas-
ingly common; in 2010, 11 new reviews were estimated
to be published daily [1]. Ideally, systematic reviews are
based on pre-defined eligibility criteria and conducted
according to a pre-defined methodological approach as
outlined in an associated protocol.
The preparation of a protocol is an essential compo-
nent of the systematic review process; it ensures that a
systematic review is carefully planned and that what is
planned is explicitly documented before the review
starts, thus promoting consistent conduct by the review
team, accountability, research integrity, and transparency
of the eventual completed review. A protocol may also
reduce arbitrariness in decision-making when extracting* Correspondence: dmoher@ohri.ca
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unless otherwise stated.and using data from primary research, since planning
provides an opportunity for the review team to antici-
pate potential problems. When clearly reported proto-
cols are made available, they enable readers to identify
deviations from planned methods in completed reviews
and whether they bias the interpretation of a review re-
sults and conclusions. Bias related to the selective
reporting of outcomes has been characterized as a ser-
ious problem in clinical research, including systematic
reviews [2-7].
Until recently, systematic review protocols were gener-
ally available only through select organizations, such as
The Cochrane [8] and Campbell Collaborations and the
Joanna Briggs Institute, for which the preparation of a
protocol is mandatory. Outside of these organizations,
the existence of a protocol is infrequently reported in
completed reviews [9,10]. Fewer than half of 300 system-
atic reviews indexed on MEDLINE in November 2004
(most recent generalizable sample; 2014 update under-
way) report working from a protocol [10], 80% of which
are non-Cochrane affiliated. Of the non-Cochrane thera-
peutic reviews, only 11% mentioned the existence of a
protocol [10]. The majority of reviews in health care areThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[10]. The paucity of protocols may be due, in part, to the
authors’ lack of knowledge about how to write them and
what to include. Currently, little succinct guidance is
available for those preparing systematic review protocols,
although the recent Standards for Systematic Reviews
prepared by the Institute of Medicine (IOM) provide
some guidance toward addressing this gap [11].
Many groups have called for the widespread preparation
and registration of systematic review protocols in order
to increase the availability and accessibility of a priori
methods for systematic reviews [12-14]. Such an effort
may reduce the duplication of effort [15] and reduce
the publication bias of systematic reviews. This chal-
lenge has been taken up by the Centre for Reviews and
Dissemination, University of York, which has spearheaded
the establishment of an international register—PROS-
PERO (International Prospective Register of Ongoing
Systematic Reviews, http://www.crd.york.ac.uk/prospero)
[16,17]. The register, which enables the permanent docu-
mentation of 22 mandatory (and 18 optional) items about
the a priori design and conduct of a review, was launched
in February 2011. At the time of writing, >5,000 system-
atic review protocols from over 70 countries have been
registered since its inception. Starting in October 2013,
new Cochrane protocols were and continue to be auto-
matically added to PROSPERO.
Along with the improved accessibility of protocols
through registration comes the need for strengthened
transparency, accuracy, and completeness of the reports
of protocols intended for dissemination. A template to
aid in the preparation of systematic review protocols,
such as a reporting guideline, may help achieve this. Fur-
thermore, such guidance will enable authors to create a
clear and complete document of their a priori methods,
which may facilitate the registration of key information
into the PROSPERO database. Building on an estab-
lished guideline for systematic reviews and meta-Table 1 PROSPERO and PRISMA-P
Definition and objective
PROSPERO: International Prospective
Register of Systematic Reviews
An online portal through which to
outcomes, before it is initiated [16]
reviews known before they are con
reviews [15]. In addition, by requirin
increased transparency in the revie
methods, outcomes, and analyses c
changes impact the results of a rev
PRISMA-P: Preferred Reporting Items for
Systematic Review and Meta-Analysis
Protocols
A guideline to help authors prepare
provides them with a minimum set
provide the rationale for the review
embarking on a review. Investigato
PROSPERO so that details requiring
the need for multiple amendments
from the PRISMA checklist and itemanalyses of studies evaluating health care interventions
—the Preferred Reporting Items for Systematic reviews
and Meta-Analyses (PRISMA, www.prisma-statement.
org) [12,13]—we have developed PRISMA for Protocols
(PRISMA-P) 2014. Table 1 summarizes the difference
in intentions between PRISMA-P and PROSPERO.
The aim of PRISMA-P 2015 is to improve the quality
of systematic review protocols, similar to the impact
achieved by other reporting guidelines [18-20]. By help-
ing authors document an a priori road map of their sys-
tematic review, PRISMA-P also has the potential to
improve the conduct of systematic reviews, as has been
suggested of other reporting guidelines [21]. This State-
ment paper summarizes the development of the guide-
line and presents the PRISMA-P checklist.
Terminology
There is no standard definition for a systematic review
and meta-analysis protocol, and we note that some ter-
minology contained within these definitions may carry
different meanings for different readers (i.e., ‘systematic
search’). The terms ‘systematic review’ , ‘meta-analysis,’
and ‘protocol’ are defined in Table 2. The former two
terms are in accordance with the definitions reported in
the PRISMA Statement [13] and are in line with those
used by the Agency for Healthcare Research and Qual-
ity’s Evidence-based Practice Center (EPC) program [22],
The Cochrane Collaboration [23], and the 2011 guidance
from the Institute of Medicine [11]. The definition pro-
vided is a culmination of the terminology used by the
Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) 2013 initiative [24], the PROS-
PERO register, and the IOM Standards (Table 2).
Scope
The PRISMA-P checklist is intended primarily for the
preparation of protocols of systematic reviews and meta-
analyses that summarize aggregate data from studies,register the intention to conduct a systematic review, with health-related
. One of the main goals of PROSPERO is to make the intent of systematic
ducted in order to reduce the unplanned duplication of systematic
g the documentation of a priori methods, the register facilitates
w process by allowing readers of systematic reviews to compare
arried out with those planned in advance and judge whether such
iew.
protocols for planned systematic reviews and meta-analyses that
of items to be included in the protocol. A protocol is intended to
and pre-planned methodological and analytic approach, prior to
rs should prepare a review protocol in advance of registering it in
further consideration may be thought through in advance, avoiding
to registration information. PRISMA-P items have been derived largely
s of the PROSPERO register, in order to facilitate seamless registration.
Table 2 PRISMA-P terminology
Term Definition
Systematic
review
A systematic review attempts to collate all relevant evidences that fits pre-specified eligibility criteria to answer a specific research
question. It uses explicit, systematic methods to minimize bias in the identification, selection, synthesis, and summary of studies.
When done well, this provides reliable findings from which conclusions can be drawn and decisions made [25,26]. The key
characteristics of a systematic review are (a) a clearly stated set of objectives with an explicit, reproducible methodology; (b) a
systematic search that attempts to identify all studies that would meet the eligibility criteria; (c) an assessment of the validity of the
findings of the included studies (e.g., assessment of risk of bias and confidence in cumulative estimates); and (d) systematic
presentation, and synthesis, of the characteristics and findings of the included studies
Meta-analysis Meta-analysis is the use of statistical techniques to combine and summarize the results of multiple studies; they may or may be
contained within a systematic review. By combining data from several studies, meta-analyses can provide more precise estimates
of the effects of health care than those derived from the individual studies
Protocol In the context of systematic reviews and meta-analyses, a protocol is a document that presents an explicit plan for a systematic
review. The protocol details the rationale and a priori methodological and analytical approach of the review
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tions. There are many review types that are outside of
this scope. As such, given the general lack of protocol
guidance for other types of reviews, we encourage re-
viewers preparing any type of review protocol to make
use of PRISMA-P as applicable. Readers can also use the
checklist to assess the completeness of the reporting of
published protocols. However, it is not recommended to
use the checklist as an assessment tool to gauge the ap-
propriateness of the methods of a systematic review
protocol; it has not been validated for that purpose.Development of PRISMA-P 2015
An international steering committee (MC, DG, AL, DM,
MP, PS, and LAS) comprising members with wide-ranging
experience in systematic review methodology, protocol
registry development, and reporting guideline development
led the development of PRISMA-P, coordinated by LS. The
process proposed by the Enhancing the Quality and Trans-
parency of Health Research (EQUATOR) Network was
used to guide PRISMA-P development [27]. The process
has 18 step-by-step recommendations grouped into five
main stages:
1. Initial steps (determine the need for a reporting
guideline);
2. Pre-meeting activities (identify contributors, conduct
Delphi exercise, generate a list of potential items,
and prepare for face-to-face meeting);
3. Face-to-face consensus meeting (present results of
pre-meeting activities and relevant evidence);
4. Post-meeting activities (develop guidance Statement,
Explanation and Elaboration document, and a
publication strategy);
5. Post-publication activities (encourage uptake of
guideline).
The first stage, ‘Initial steps,’ was described above; de-
tails of the remaining four steps are below.Pre-meeting activities
In developing the PRISMA-P checklist, the steering
committee compiled a list of items from various tools
relating to the preparation of systematic review proto-
cols for discussion at a consensus meeting of experts.
Specifically, we mapped items from a Delphi exercise
carried out during the development of PROSPERO [28],
PROSPERO register items, PRISMA checklist items [13],
SPIRIT 2013 checklist items [29], and items of IOM
Standard 2.6 [11] against each other to identify unique
and overlapping concepts. Lessons learned from the de-
velopment of the SPIRIT checklist with respect to the
concept and content of research protocols were used to
guide discussion and debate at the meeting.PRISMA-P consensus meeting
Twenty-three international experts attended the
PRISMA-P consensus meeting on June 23–24, 2011, in
Rockville, MD, USA to gain consensus on and reduce
the number of potential PRISMA-P items. Delegates in-
cluded journal editors, systematic review methodologists
(including directors and representatives from inter-
national Cochrane Centres, Agency for Healthcare Re-
search and Quality’s (AHRQ’s) Evidence-based Practice
Centres, and the UK National Institute for Health Re-
search), reporting guideline developers, information spe-
cialists, biostatisticians, and health research funders.
Through group discussion at the meeting, 38 potential
checklist items were reduced to 22.Post-meeting activities
Following the meeting, the steering committee revised
the draft 22-item checklist and refined their wording
such that they accurately reflected meeting discussions.
The draft checklist was also presented to the PROS-
PERO group, at a scientific meeting of the Cochrane
Collaboration, for input and feedback and to AHRQ’s
Learning Network. After each of these reviews, the steer-
ing committee made minor amendments to the items.
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for critical input.
The PRISMA-P 2015 checklist
The final PRISMA-P 2015 checklist contains 17 numbered
items (26 including sub-items) Items are categorized into
three main sections: administrative information, introduc-
tion, and methods (Table 3).
We made a conscious effort to harmonize the PRISMA-
P checklist items with the items of the PRISMA checklist
to facilitate authors in transitioning their protocol into
a report of a systematic review. Thirteen PRISMA-P
sub-items have existing PRISMA counterparts. Where
PRISMA wording or content did not sufficiently ad-
dress protocol reporting, checklist items were modified.
Readers familiar with PRISMA will notice that PRISMA-
P does not contain a flow diagram documenting the flow
of studies throughout the systematic review process. Such
documentation is possible only after a review has been car-
ried out and remains an essential component to include in
the report of a completed systematic review or meta-
analysis; for further guidance, see the PRISMA Explanation
and Elaboration document [12].
We strongly recommend that the present document
and the accompanying PRISMA-P 2015 Explanation and
Elaboration document [30], which includes examples of
good reporting, rationale, and evidence (where available),
be read together with the PRISMA-P 2015 checklist.
PRISMA-P 2015 explanation and elaboration
Once the steering committee prepared the PRISMA-P
2015 Statement and checklist, they drafted the content
of an Explanation and Elaboration document, with as-
sistance from the larger PRISMA-P group. The explana-
tory text was derived largely from discussions at the
PRISMA-P meeting (recorded at the time) as well as the
PRISMA Explanation and Elaboration document [12].
Examples of well-reported PRISMA-P items came from
protocols registered in the PROSPERO database,
AHRQ’s EPC Program, and the Cochrane Database of
Systematic Reviews or those published elsewhere. After
the entire group had an opportunity to suggest addi-
tions, deletions, and changes, the steering committee
combined all amendments to create the PRISMA-P 2014
Explanation and Elaboration document [30].
Post-publication activities
The post-publication activities recommended by EQUA-
TOR include seeking and responding to criticism, encour-
aging the endorsement of and adherence to the guideline
from various stakeholders, translating the guideline into
other languages, evaluating its impact, ensuring website
development, and updating of the guideline. The
PRISMA-P 2015 checklist and related publications arefreely available on the websites of the PRISMA Group
(www.prisma-statement.org) and EQUATOR Network
(www.equator-network.org). The PROSPERO register
also contains a link to the guidance to encourage regis-
trants to prepare a complete documentation of their
protocol if they have not done so already.
We plan to develop an educational webinar about the
rationale, usefulness, and potential impact of PRISMA-P,
similar to what was done for PRISMA [31]. In addition,
the potential for PRISMA-P 2015 to be used as an educa-
tional tool for authors, peer reviewers, and editors will be
explored. Targeted implementation activities for PRISMA-
P will be developed in a systematic manner together with
experts in knowledge translation. The PRISMA website
and social media (@PRISMAStatement, www.twitter.
com/PRISMAStatement) will be used to make an-
nouncements about the launch of PRISMA-P and edu-
cational initiatives.
Endorsement
We encourage journals publishing systematic review prod-
ucts to modify their ‘Instructions for Authors’ section to
endorse PRISMA-P 2015 and to consider publishing sys-
tematic review protocols, if they do not do so already. We
plan to communicate with known endorsers of PRISMA
(http://prisma-statement.org/endorsers.htm) as well as to
other, relevant non-endorsing journals, to ask them to
consider extending their support to PRISMA-P.
To help ensure optimal uptake by systematic reviewers,
we propose a uniform endorsement policy across organi-
zations and journals involved in the development and
publication of systematic review protocols, demonstrated
by the adoption of the following statement:
‘[this organization/journal] requires a completed
PRISMA-P 2015 checklist as a condition of submission
of systematic review protocols. We recommend that,
while completing the PRISMA-P 2015 checklist, you
ensure your protocol addresses all items. Taking the
time to ensure that your protocol adheres to these
basic reporting elements will improve your manuscript
and potentially enhance its chances of eventual
acceptance.’
Such a statement could be included in a journal’s ‘In-
structions to Authors,’ or for funding agencies and those
commissioning systematic reviews, in their Application
Guidelines, recommending that applicants developing
the proposals of systematic reviews for funding use
PRISMA-P 2014. Peer reviewers and scientific commit-
tees can also use the checklist to gauge the extent to
which protocols include necessary information.
As has been done for previous reporting guidelines
[18,32] we plan to evaluate whether and to what degree
Table 3 PRISMA-P 2015 checklist: recommended items to include in a systematic review protocola
Section/topic Item # Checklist item
ADMINISTRATIVE INFORMATION
Title
Identification 1a Identify the report as a protocol of a systematic review
Update 1b If the protocol is for an update of a previous systematic review, identify as such
Registration 2 If registered, provide the name of the registry (e.g., PROSPERO) and registration number
Authors
Contact 3a Provide name, institutional affiliation, and e-mail address of all protocol authors; provide physical
mailing address of corresponding author
Contributions 3b Describe contributions of protocol authors and identify the guarantor of the review
Amendments 4 If the protocol represents an amendment of a previously completed or published protocol,
identify as such and list changes; otherwise, state plan for documenting important protocol
amendments
Support
Sources 5a Indicate sources of financial or other support for the review
Sponsor 5b Provide name for the review funder and/or sponsor
Role of sponsor/
funder
5c Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol
INTRODUCTION
Rationale 6 Describe the rationale for the review in the context of what is already known
Objectives 7 Provide an explicit statement of the question(s) the review will address with reference to participants,
interventions, comparators, and outcomes (PICO)
METHODS
Eligibility criteria 8 Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report characteristics
(e.g., years considered, language, publication status) to be used as criteria for eligibility for the review
Information sources 9 Describe all intended information sources (e.g., electronic databases, contact with study authors,
trial registers, or other grey literature sources) with planned dates of coverage
Search strategy 10 Present draft of search strategy to be used for at least one electronic database, including planned
limits, such that it could be repeated
Study records
Data management 11a Describe the mechanism(s) that will be used to manage records and data throughout the review
Selection process 11b State the process that will be used for selecting studies (e.g., two independent reviewers) through each
phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis)
Data collection process 11c Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in
duplicate), any processes for obtaining and confirming data from investigators
Data items 12 List and define all variables for which data will be sought (e.g., PICO items, funding sources), any
pre-planned data assumptions and simplifications
Outcomes and
prioritization
13 List and define all outcomes for which data will be sought, including prioritization of main and
additional outcomes, with rationale
Risk of bias in
individual studies
14 Describe anticipated methods for assessing risk of bias of individual studies, including whether this will
be done at the outcome or study level, or both; state how this information will be used in data synthesis
Data
Synthesis 15a Describe criteria under which study data will be quantitatively synthesized
15b If data are appropriate for quantitative synthesis, describe planned summary measures, methods of
handling data, and methods of combining data from studies, including any planned exploration of
consistency (e.g., I2, Kendall’s tau)
15c Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses, meta-regression)
15d If quantitative synthesis is not appropriate, describe the type of summary planned
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Table 3 PRISMA-P 2015 checklist: recommended items to include in a systematic review protocola (Continued)
Meta-bias(es) 16 Specify any planned assessment of meta-bias(es) (e.g., publication bias across studies, selective
reporting within studies)
Confidence in
cumulative evidence
17 Describe how the strength of the body of evidence will be assessed (e.g., GRADE)
PRISMA-P Preferred Reporting Items for Systematic review and Meta-Analysis Protocols.
aIt is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration [30] for important clarification on the items.
Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed
under a Creative Commons Attribution License 4.0.
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tially by other organizations) influences the complete-
ness of reported protocols. Such an evaluation will be
planned after allowing sufficient time for the wide dis-
semination of PRISMA-P 2015.Table 4 Proposed stakeholders, actions, and potential benefi
Stakeholder Proposed action
Funders Promote or mandate adherence to PRISMA-P
a template for systematic review proposals fo
Systematic review authors/
groups/organizations
Use/adhere to PRISMA-P during protocol dev
PROSPERO (and other
review registries)
Encourage the development of PRISMA-P-bas
Practice guideline
developers
Use PRISMA-P to gauge the completeness of
facilitate detection of selective reporting whe
reviews for guideline inclusion
Policymakers Advocate use of PRISMA-P by those funding
out systematic reviews
Journal editors Encourage compliance to PRISMA-P for autho
protocols for publication
Offer PRISMA-P as a template to assist in prot
writing for publication
Educators Use PRISMA-P as a training tool
Encourage adherence in students submitting
for coursework
Students Develop protocols for coursework or researchImplementation
The current system of implementing reporting guide-
lines is not optimal. At present, their primary mechan-
ism of uptake is through endorsement by journals at
their discretion, if at all. In journals that do endorsets for supporting adherence to PRISMA-P
Potential benefits
or use PRISMA-P as
r grant applications
Improved quality, completeness, and consistency
of systematic review proposal submissions
Standardized protocol content will improve peer
review efficiency and investigator understanding
of requirements
elopment Improved quality, completeness, and consistency
of protocol content
Enables reviewers to anticipate and avoid future
changes to review methods (i.e., outcomes)
Increased awareness of minimum content for
protocol reporting
Improved completeness of reporting of
completed reviews
ed protocols Improved quality of registry entries
Improved consistency across registry entries,
protocols, and systematic reviews
protocols and
n considering
Enables easy comparison across protocols, registry
entries, and completed systematic reviews
and carrying May yield better quality, more complete, and more
consistent reviews to inform decision-making
rs submitting Improved quality, completeness, and consistency
of protocols over those published in journals not
endorsing PRISMA-P
ocol Increased efficiency in protocol peer and
author understanding of journal requirements
Improved transparency and interpretation
of reviews by readers
Simplified teaching and grading of protocols
protocols Improved quality, completeness, and
consistency of protocol content
using PRISMA-P Improved understanding of the minimum
protocol content
Well-trained systematic reviewer going
into the workforce
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vague, leaving authors unclear on what they are sup-
posed to do with a given reporting guideline during the
submission process [33]. Furthermore, policies around
how journal editors and peer reviewers should ensure
and/or enforce adherence to reporting checklists are
even less clear, if they exist at all [34]. Other barriers to
implementation may include a lack of awareness of the
guideline and perceived burden of using a reporting
guideline checklist during the editorial process [35].
Some well-known checklists, such as PRISMA, include
a column to the right of the main checklists in which
users report the page number on which a specific item is
reported. This was initially intended to help authors en-
sure each checklist item is addressed and to aid peer re-
viewers in locating reported text for each item within a
document. However, this system is not optimal. One
major problem is that peer reviewers still have to search
within a considerable body of text to locate the exact
text describing a checklist item. When multiple items
are listed separately but reported together or vice versa,
this problem is compounded, because exactly which
content pertains to each item may remain unclear.
The lack of implementation and adherence to report-
ing guidelines is systemic; additional authorities encoun-
tered early in the research process should promote a
clearer message about author adherence to reporting
standards if improvements in reporting are to be made.
In targeting protocols of systematic reviews, PRISMA-P
has a unique opportunity to not only affect the way in
which protocols are reported but to also impact the way
in which reviews are eventually conducted, perhaps
allowing for a more seamless transition into a com-
pletely reported systematic review.
To overcome known challenges with reporting guideline
uptake [36,37], we are developing a prospective imple-
mentation strategy for PRISMA-P 2015 using knowledge
translation principles involving theoretically derived inter-
ventions [37] which have demonstrated effectiveness in
the development of implementation interventions for clin-
ical practice guidelines [38,39]. An initial list of proposed
stakeholders who can assist in the implementation of
PRISMA-P, along with proposed actions and benefits, is
provided in Table 4.
Discussion
Studies comparing trial protocols to final reports have
widely documented both the presence and the extent of
reporting biases in publications of randomized trials
[2,40]. Protocols for systematic reviews are rarely available
for such comparisons, with the exception of select organi-
zations. Of 288 reviews with available protocols in a 2006/
2007 cohort, 64 (22%) were observed to have at least one
discrepant outcome with their completed reviews; only 4described reasons for the change in the completed review
[3]. Discrepant outcomes added or upgraded from second-
ary to primary at the review stage were more likely to be
statistically significant than those outcomes that had not
changed. This practice (i.e., including, excluding, or chan-
ging outcomes in association with the strength or direc-
tion of findings) has the potential to bias the findings of
any meta-analysis and the review’s conclusions. As review
protocols are expected to become increasingly available
with the advent of PROSPERO, clear reporting will be-
come essential to facilitate the identification of discrepan-
cies between protocol and review by readers and help
them determine whether they need to be cautious in inter-
preting findings.
Reporting and publishing protocols is an important step
in increasing the transparency of the research process and
reliability of published papers. For example, some journals
require a copy of the protocol as part of the peer review
process of randomized trials. As of 1 March 2014, BioMed
Central has published 4,158 trial protocols across 66 of its
258 open-access journals, including 1,026 in Trials. Sys-
tematic Reviews, a BioMed Central journal launched in
February 2012, is committed to publishing systematic re-
view products, including protocols [41], and has published
142 protocols since inception (to 8 June 2014).
Journals, granting agencies, and systematic review or-
ganizations are encouraged to endorse PRISMA-P 2015
in their ‘Instructions to Authors’ and guidance for appli-
cants and to implement its use during their peer review
process of systematic review proposals. Reviewers are
encouraged to use the PRISMA-P checklist and Explan-
ation and Elaboration [30] document to guide them
through the documentation of a protocol. Doing so will
enhance the completeness of reporting of review proto-
cols, facilitate the assessment of potential in systematic
reviews, and hopefully strengthen the methodological
quality and reliability of completed systematic reviews.
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